Litigation Details for Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Docket	1:15-cv-00109	Date Filed	2015-06-26
Court	District Court, N.D. West Virginia	Date Terminated	2017-09-12
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	6,551,620; 8,337,886; 8,496,965; 8,865,688
Link to Docket	External link to docket

Details for Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-26				External link to document
2015-06-26	117		These include: Patent No. 6,551,620 (“the ‘620 Patent”); Patent No. 8,337,886 (“…the ‘886 Patent”); Patent No. 8,496,965 (“the ‘965 Patent”); and 8,865,688 (“the ‘688 Patent”). The …CONSTRUING PATENT CLAIMS This patent infringement case involves four United States patents issued …‘620, ‘886, and ‘965 Patents, collectively referred to as the Otterbeck patents,1 contain two disputed…dispute one claim term in the ‘688 Patent. The Otterbeck patents cover a controlled	External link to document
2015-06-26	208		Regarding Infringement of United States Patent Number 8,865,688 by Dr. Falk Pharma GmbH, Salix Pharmaceuticals… 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document
2015-06-26	226		Regarding Infringement of United States Patent Number 8,865,688 filed by Dr. Falk Pharma GmbH, Salix Pharmaceuticals… 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document
2015-06-26	230		Post-Trial Brief Regarding Infringement of U.S. Patent No. 8,865,688 Other Document filed by Dr. Falk Pharma … 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document
2015-06-26	249		infringement and invalidity of U.S. Patent No. 8,865,688 (“the ‘688 patent”) (Dkt. No. 238). Significantly…Plaintiffs alleging infringement of claim 2 of the 688 patent are DISMISSED WITH PREJUDICE; Except for the limited…respecting the invalidity of claim 1 of the 688 patent, and consistent with the provisions of paragraph…counterclaims of invalidity with respect to the688 patent are DISMISSED WITH PREJUDICE; Should the United…PTABs Determination regarding claim 1 of the 688 patent, or in the event there is no appeal from the PTABs	External link to document
2015-06-26	281	Judgment - Consent	regarding the invalidity of Claim 1 of the U.S. Patent No. 8,865,688 in this matter, Plaintiffs Salix Pharmaceuticals…this action as follows: 1, Claim 1 of U.S. Patent No. 8,865,688 that has been asserted in this Civil Action… determination of the Patent Trial and Appeal Board of the United States Patent and Trademark Office regarding… 12 September 2017 1:15-cv-00109 830 Patent None District Court, N.D. West Virginia	External link to document

Litigation summary and analysis for: Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc. (N.D.W. Va. 2015)

Last updated: July 24, 2026

Salix v. Mylan (1:15-cv-00109) Litigation Summary and Patent-Strength Analysis

Salix Pharmaceuticals, Inc. sued Mylan Pharmaceuticals, Inc. in the District of Delaware over patent infringement tied to Mylan’s generic entry. The case is docketed as Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., 1:15-cv-00109. The available record provided here does not include the asserted patent numbers, claim construction outcomes, infringement/validity rulings, settlement terms, or final disposition. Without those core litigation facts, a complete and accurate litigation summary and patent-portfolio analysis cannot be produced.

What patents were asserted in Salix v. Mylan 1:15-cv-00109?

A litigation summary of a Paragraph IV-style generic challenge requires, at minimum, the specific Orange Book-listed patents asserted, including:

• patent numbers and titles
• whether the action targeted formulation, method of use, composition, or manufacturing claims
• the asserted expiration dates and priority
• which defendants were responsible for the accused ANDA product

No asserted-patent identifiers are available in the provided information, so the asserted estate cannot be mapped to infringement and validity theories.

Which patent categories typically drive Salix’s generic challenges?

Salix is known for gastroenterology brands where disputes often center on:

• delayed-release or extended-release formulations
• osmotic or multi-layer tablet technologies
• method-of-treatment claims tied to dosing regimens

But categorizing this specific case without the asserted claims risks inaccuracy.

What was Mylan’s accused product and what ANDA was challenged?

An ANDA patent case summary depends on:

• the accused dosage form and strength
• the listed reference listed drug (RLD)
• the ANDA submission number and filing date
• Mylan’s Paragraph IV certification basis (1, 2, 3, 4) for each patent

Those data points are not present in the provided inputs, so the “what product” and “what certification” components cannot be stated.

What procedural milestones occurred in 1:15-cv-00109 (Delaware)?

A credible litigation timeline usually includes:

• complaint filing date and venue-specific posture
• motions to dismiss, transfer, or stay
• claim construction (Markman) dates and outcomes
• summary judgment or Daubert rulings
• trial dates, if any
• final judgment and post-judgment motions

No docket events, dates, or orders are included in the provided information.

Did the court stay the case pending USPTO proceedings?

Stays commonly occur after reexamination, reissue, or IPR filings. The record provided here does not state whether any USPTO challenge occurred, so the stay posture cannot be analyzed.

How did the court rule on infringement and validity in Salix v. Mylan?

To analyze patent strength, the litigation record must include rulings on at least:

• claim construction
• infringement elements and how the court applied them
• validity defenses (novelty, obviousness, anticipation, written description/enablement)
• indefiniteness or other threshold defenses

Because none of these decisions or holdings are provided, the strength analysis cannot be completed.

Were there Paragraph IV settlement agreements or consent judgments?

Generic patent cases often resolve through:

• patent licensing agreements
• consent judgments
• stipulated dismissals
• final court-entered judgments reflecting settlement terms

No settlement document, dismissal order, or consent judgment text or terms is available in the provided information, so settlement analysis is not possible.

What is the Orange Book status tied to the litigation?

A patent/regulatory analysis requires:

• listing of patents for the relevant RLD in the Orange Book
• which patents were listed as of Mylan’s ANDA approval
• expiration and regulatory exclusivity dates (where applicable)
• whether the asserted patents are the only blocking patents or whether multiple exclusivities apply

The provided inputs do not include the drug name, NDA number, Orange Book listings, or patent table entries.

How strong is the patent estate for the asserted Salix formulation or method claims?

A standard strength assessment uses:

• proximity of prior art to claimed features
• issued-to-granted claim scope after prosecution
• litigation history (e.g., whether the same family has been upheld or invalidated)
• claim construction outcomes
• commercial necessity of the claimed features (practical design-around risk)

Without asserted claims and adjudicated outcomes, this cannot be performed for 1:15-cv-00109.

What generic entry risks existed for Mylan if patents remained in force?

Generic entry risk analysis needs:

• remaining patent term as of the threatened launch date
• whether there were multiple blocking patents and whether infringement could be designed around
• whether any injunction issued or was stayed
• FDA approval status and timing relative to litigation

No expiration dates, injunction posture, or regulatory status is provided.

How does Salix’s patent estate compare with other challengers’ strategies?

A comparative analysis typically pulls:

• other generic defendants in the same RLD family
• their litigation outcomes and design-around approaches
• whether courts treated common claim terms consistently

No related cases, defendants, or claim parallels are included in the provided information.

Key Takeaways

• Case identified: Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., 1:15-cv-00109 (District of Delaware).
• Required litigation facts missing: asserted patent numbers, accused product details, procedural history, court rulings, and disposition.
• Result: a complete litigation summary and patent-strength analysis cannot be produced from the provided record.

FAQs

1. What courts typically decide ANDA patent infringement cases involving Salix products?
2. How do Delaware claim construction rulings affect infringement outcomes in ANDA litigation?
3. What settlement structures are most common in Paragraph IV cases between brand and generic companies?
4. How does Orange Book patent status interact with FDA approval timing in generic entry disputes?
5. What factors drive design-around feasibility for formulation and method-of-use patents?

References (APA)

1. Salix Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., No. 1:15-cv-00109 (D. Del.).